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TCT-715
Transcatheter Occlusion of the Patent Ductus Arteriosus with the new ADO II
Amplatzer Device
Norberto Herrera Gómez, Antonio Luis Arrebola-Moreno, Joaquín Sánchez-Gila,
Eduardo Molina-Navarro, Carlos Briales, José Antonio Ramírez-Hernández, José
Antonio Romero-Hinojosa, Rafael Melgares-Moreno
Cardiology, H.U.Virgen de las Nieves, Granada, Spain
Background: Transcatheter device closure is the standard of care for PDA in children
and adults. We sought to assess patients with persistent ductus arteriosus (PDA) in
whom a percutaneous closure was performed by the new ADO II Amplatzer device
Methods: From October 2009 to May 2011, 25 patients (P) have been intervened using
the ADO II device. Basal characteristics, any events during the procedure and follow-
up were analyzed.
Results: From the 25 P, 2 were adults, 14 female, mean age 12±8 years (median 8,
maximum 73, minimum 1 month), mean weight 33±19kg (max 86, min 3), mean height
129 cm (max 170, min 50). 20 P presented isolated PDA, 4 P had persistent foramen
ovale, 1P had a muscular intraventricular communication. 19 P were asymptomatic.
The indication was left ventricular (LV) dilatation in 8P and heart failure in 2P. In the
transthoracic echocadiogram (TTE) 10 P(40%) presented ventricular dilatation and 2
P(8%) LV systolic dysfunction. The PDA dimensions were higher in the angiogram
than in the TTE (mean diameter 3.22±2.6 vs 2.9±0.9mm, length 8.3±1.5 vs 7.33+/-
0.57 cm)p<0.01. The mean pulmonary pressure was 20±6 mm Hg(max 33, min 12). A
retrograde (femoral artery approach) implantation was performed in 24 P (96%). The
device was successfully implanted in 24 P(96%) with a mean fluoroscopy time of 6±3
min without any complications. A ADO I device was finally implanted (anterograde
approach) in 1 P. A moderate shunt remained in 1 P after the procedure and the device
migrated to the pulmonary branch in 24 hours. In the follow-up (median 13 months),
the remaining 24 patients presented no events or significant shunt
Conclusion: The PDA closure with ADO II device is an easy and effective procedure.
An appropriated closure of the defect is feasible and safe.
TCT-716
Complications Leading to Explantation of PFO Closure Devices - A Multicenter
Review
Swarnendra Verma, Jonathan Tobis
UCLA Medical Center (David Geffen School of Medicine), Los Angeles, CA
Background: Our objective was to examine the frequency and causes for surgical
explantation of PFO closure devices. Patent Foramen Ovale (PFO) has been linked
with cryptogenic strokes, recurrent transient neurologic deficits, sleep apnea,
decompression illness, and migraines. Approximately 20% of adults are suspected to
have a PFO, and 8,000 PFO closure procedures are performed each year in the United
States, utilizing various devices. Several randomized trials are in progress to determine
if PFO closure is preferable to medical management in the treatment of patients with
cryptogenic strokes or migraine. The majority of PFO closures are performed off-label
as there is no FDA approval for use of any device to close a PFO. As data is
accumulating on the benefits of implanting PFO closure devices, it is also important
to examine complications that may occur. There have been isolated reports of patients
that needed to have their device removed. Because extraction of a PFO device requires
open heart surgery, it would be useful to determine the relative frequency of this
unfortunate event.
Methods: We performed a database review to identify the frequency and causes of
PFO device explantation, examining 18 PFO closure centers from Europe and the
United States.
Results: Of the 13,736 percutaneous PFO device implantations performed over the
past 9 years at these 18 institutions, 38 devices [0.28% (95% CI, .20% - .37%)] required
surgical removal. There were a wide range of causes cited for these removals. The
most common cause for explantation was chest pain (n=14), often determined to be
secondary to nickel allergy to the PFO device. Other causes for explantation included
persistence of a residual shunt (12), the presence of thrombus on the device (4),
pericardial effusion (2), perforation of the atrium or aortic root (2), recurrent strokes
(1), the development of endocarditis (1), and undocumented reasons (2).
Conclusion: The vast majority of PFO closure procedures are performed safely with
minimal complications. However, there is a small (0.28%) incidence of severe long-
term problems associated with PFO closure that may require surgical removal of the
device. In addition, the frequency of surgical explantation was found to be device
dependent; some of these devices appear to be safer than others.
TCT-717
Comparison of Long-term Follow-up After Endovascular Stent Placement
Between Patients with Native Coarctation or Post-surgical Recoarctation
Maria Giulia Gagliardi1, Mara Pilati1, Francesco Pelliccia2, Arianna Viola1,
Giuseppe Bolla1, Paolo Guccione1, Giacomo Pongiglione1
1Bambino Gesù, Rome, Italy; 2San Filippo Neri Hospital, Rome, Italy
Background: Endovascular stent placement is an established therapy for native
coarctation of the aorta or recoarctation in older children where stents capable of
expansion to adult size can be placed safely. We investigated if long-term outcome
after endovascular stent placement is different between patients with native aortic
coarctation or post-surgical recoarctation.
Methods: Between 2006 and 2010, 35 patients with aortic arch obstruction were
treated with endovascular stent placement (21 males, median age: 15 years - range: 9-
31; mean weight: 45 kg – range: 20-87). Ten patients had native aortic arch obstruction
(Group A) and 25 patients had recoarctation after surgery (Group B). Major end-points
were procedural success, significant recurrent obstruction, and freedom from
unplanned repeat intervention.
Results: Clinical features at baseline were similar in the two groups. Successful device
deployment was achieved in all patients. Stent deployment increased significantly
(p<0.05) the minimum diameter of the CoA both in Group A (from 8.0 to 18.5 mm)
and Group B (from 8.5 to 19.0 mm), as well as the ratio of the coarctation diameter to
the descending aorta diameter (CoA/DAo) both in Group A (from 0.42 to 1.05) and
Group B (from 0.46 to 1.00). Similarly, the systolic gradient decreased significantly
(p=0.001) either in Group A (from 23.0 to 2.0 mm Hg) or in Group B (from 24.0 to
2.8 mm Hg). After stent implantation, no difference between groups were found in
CoA/DAo ratio, residual systolic gradient, and magnitude of decrease in systolic
gradient. There were no significant complications in patients under 30 kg. During a
median follow-up of 2.5 years (range 1-5 years), no patient died and 6 patients (2
patients of Group A and 4 patients of Group B) had repeat angioplasty at a median
time interval of 0.77 years (range: 0.17-2.76 years) after the index procedure. No other
long-term complication was observed.
Conclusion: Endovascular stent placement is a therapeutic option in aortic coarctation
which offers comparable benefits in native and post-surgical cases.
TCT-718
Pre-Closure of Large Sized Venous and Arterial Sheath Access Sites in Adults
Undergoing Transcatheter Structural Interventions
Tahir Hamid1, 2, Charlene Pius1, Rajinikanth Rajagopal1, Bernard Clarke1, Vaikom S
Mahadevan1
1Manchester Heart Centre, Manchester Royal Infirmary, Manchester, United
Kingdom; 2Royal Blackburn hospital, Blackburn, United Kingdom
Background: BACKGROUND:- Patients requiring congenital and structural heart
interventions often require large-sized sheath insertion into femoral veins and arteries.
Clinical outcome data on the use of suture-mediated devices for femoral venous access
site closure is limited. OBJECTIVE:- To assess the efficacy of the Perclose ™ Suture-
mediated device using the pre closure technique, in achieving haemostasis in femoral
venous and arterial sites following large sheath insertion(≥8Fr).
Methods: 306 consecutive patients underwent 333 access site closures with the
Perclose device™ using the pre closure technique. There were 175 (57%) women,
mean age 46 (±11) years, 240/333(72%) had femoral venous and 93/333 (28%) femoral
arterial access site preclosure. 289/306 (94%) received heparin. Mean venous access
site sheath diameter was 11 Fr and arterial was 12Fr.
Results: Immediate haemostasis (<2 minutes) was achieved in 331/333 (99%) sites.
Two patients (0.6%) had a major complication. Short term follow up at 3 months
revealed no evidence of haematoma or fistula formation or clinical evidence of vessel
occlusion. On Medium term follow up (mean follow-up of 14 ± 12 and median of 12.4
months) no complications were seen in the arterial and venous access sites. Perclose
devices were equally successful in both femoral arterial and venous sites closures(
Table 1).
Types of procedures performed
Conclusion: Pre-closure of large-size femoral venous and arterial access sheath sites
using the suture-mediated Perclose device™ is efficacious in achieving rapid
haemostasis in the presence of anticoagulation with no complications on the venous
site and very low complication rate on the arterial site.
TCT-719
A New Anatomical Classification of the Left Atrial Appendage Based on
Carto/CT/MR. Implications for the Implantation of Left Atrial Apppendage
Closure Device
José Ramón López-Mínguez1, Reyes González1, Manolo Doblado1, Concepción
Fernández1, Victoria Millán1, Juan M Nogales1, Antonio Merchán1, Margarita
Murillo2, Damián Sánchez Quintana2
1Cardiology, Infanta Cristina University Hospital, Badajoz, Spain; 2Extremadura
University, Badajoz, Spain
Background: Knowledge of left atrial appendage (LAA) anatomy could have a
favorable impact on the safe implantation of LAA closure devices.The purpose of this
study was to assess anatomical features of the LAA presaging greater complexity of
implantation of closure devices.
Methods: The present study considers 25 consecutive patients assigned for LAA
closure were studied by MRI or CT scan with integration of 3D left atrium (LA), LAA,
and pulmonary vein (PV) into an electroanatomic mapping system providing
endocardial and epicardial views of these structures. In addition, the take off position
of the LAA was studied in 50 postmortem hearts, to determine whether an anatomical
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correlation with the morphology by CARTO/CT/MR existed and to assess its influence
on device implantation difficulty.
Results: Our study demonstrates the existence of 3 different types of LAA ostium take-
off: Type I shows a superior and anterior os take-off, with a wide and short left lateral
ridge (LLR) (53%). Type II shows the ostium is similar to type I but the LLR is long
and narrow, causing the entrance vestibule to the LAA ostium (limbus of the LAA) to
be very well defined (32%). Type III (15%), shows a lower and more posterior LAA
take-off with a sharp separation between the LAA and the left PV ostia; the LAA ostium
hardly shows a limbus and is located very close to the LA floor, making its cannulation
extremely difficult leading to greater complexity in the implantation of the device
(procedure time: 91.6±37.6 vs 119.6±0.57 p:0.015).
Morphological data of the left atrium and type of left atrial appendage
LLR:Left lateral ridge
Conclusion: The use of CARTO/CT/MR could be a useful means of defining different
types of LAA take-offs, which could have prognostic and strategic implications for the
implantation of LAA closure devices.
TCT-720
Percutaneous Closure of the Left Atrial Appendage with the Amplatzer Cardiac
Plug:Initial Latin American Experience
Aníbal Agustín Damonte1, Costantino Costantini2, Marcio Montenegro3, Carlos
Pedra4, Alejandro Martinez5, Fabio Brito6, Jose Condado7, Daniel Aguirre8, Horacio
Faella9, Leon Valdivieso10, Miguel Ballarino11, Alejandro Fernandez12, Fernando
Cura13
1Interventional Cardiology, Instituto Cardiovascular de Rosario, Rosario,
Argentina; 2Hospital Cardiológico Costantini, Curitiba, Brazil; 3Instituto Estadual
de Cardiología, Rio de Janeiro, Brazil; 4Instituto Dante Pazzanese, Sao Paulo,
Brazil; 5Universidad Católica, Santiago, Chile; 6Hospital Albert Einstein, Sao
Paulo, Brazil; 7Hospital Perez Carreño, Caracas, Venezuela; 8Clínica Alemana,
Santiago, Chile; 9FLENI, Buenos Aires, Argentina; 10Fundación Favaloro, Buenos
Aires, Argentina; 11Hospital Privado, Córdoba, Argentina; 12Hospital Italiano,
Buenos Aires, Argentina; 13Instituto Cardiovascular de Buenos Aires, Buenos Aires,
Argentina
Background: Atrial fibrillation (AF)is the most common cardiac arrhythmia and a
major cause of morbidity and mortality secondary to cardioembolic stroke. In patients
with non valvular AF 90% of intracavitary thrombi form in the left atrial appendage
(LAA). Percutaneous closure of the LAA has emerged as a potential alternative to
anticoagulation therapy for the prevention of cerebrovascular events in patients with
AF and a contraindication or difficulties for oral anticoagulation. This study describes
the feasibility and in hospital results of the transcatheter closure of the LAA with the
new Amplatzer Cardiac Plug (ACP) in an initial Latin American experience.
Methods: Physician initiated retrospective registry, including all consecutive patients
with AF at high risk for cardioembolic stroke, from different Latin American hospitals
that were treated with the ACP, from August 2009 to April 2011. The procedures were
performed under general anesthesya, and transesophageal ecocardiography (TEE) and
fluoroscopic guidance.
Results: 40 patients were included. Age 72±8.7 years;male 70%; CHADS2 score
3.15±1.1 LAA neck diameter was 20.3±3.8 mm by TEE and 22.6±3.2 by angiography.
LAA occlusion was attempted and successfully achieved in all 40 patients, and in 2
cases, simultaneous closure of the LAA and PFO was performed. The implanted device
size was 25±2.9 mm. There were serious in hospital complications in 3 patients (7.5%).
1 patient experienced device embolization that required surgical retrieval, and 2 patients
presented serious pericardial effusion. There were not in hospital deaths, stroke, or
myocardial ischemia.
Conclusion: In this initial experience, percutaneous closure of the LAA with the ACP
in patients with AF at high risk of stroke was feasible, with a high technical success,
and a complications rate similar to previous reports with this and other devices during
the learning phase of the procedure.
TCT-721
Thrombi on the Amplatzer Cardiac Plug after LAA Occlusion: Evaluation of
Potential Echo Risk Factors
Björn Plicht, Philipp Kahlert, Hagen Kälsch, Thomas Buck, Raimund Erbel, Thomas
F Konorza
Cardiology Clinic, West-German Heart Center, Essen, Germany
Background: Percutaneous left atrial appendage (LAA) occlusion is a novel approach
for stroke propyhaxis in patients with atrial fibrillation (AF) and contraindications for
oral anticoagulation. The Amplatzer Cardiac Plug (ACP) device consists of a lobe
anchored in the LAA with a connected disk shielding the LAA ostium. In 6 patients
postinterventional thrombus formation on the disk was found. We analyzed pre
interventional echo parameters as possible risk factors.
Methods: LAA occlusion was performed in 34 consecutive AF patients (CHADS2
score ≥2) under concious sedation. Post interventional dual antiplatelet therapy was
initiated according to manufacturer’s instructions of use. Transthoracic (TTE) and
transesophageal echo (TEE) were performed pre interventionally, pre discharge, after
3 and 6 months. Ejection fraction (EF), left atrial volume index (LAVi), LAA velocity,
spontaneous echo contrast (SEC, scored 0-4) and transmitral gradient (TMG) were
analyzed.
Results: In 36 procedures 34 ACP were implanted successfully. 2 ACP could not be
placed due to an inappropriate anatomy. Mean occluder size was 24.1 ± 3.1 mm. In 3
patients thrombus was detected in the pre discharge TEE, in 3 further patients after 3
months. Mean EF was 50.6 ± 11.4 % in the non-thrombus vs. 39.7 ± 10.6 % in the
thrombus group (p = 0.039, significant). LAVi was 46.9 ± 20.8 vs. 56.6 ± 14.2 ml/m2
(p = 0.285), LAA velocity was 51.3 ± 25.1 vs. 36.8 ± 17.7 cm/s (p = 0.194), SEC was
1.3 ± 0.9 vs. 1.5 ± 0.5 (p = 0.632) and TMG was 1.9 ± 2.0 vs. 1.4 ±0.5 mmHg (p =
0.568).
Thrombus formation after implantation oft he ACP into the LAA (left 2D, right
RT3D TEE).
Conclusion: Thrombus formation on the new ACP device is a serious complication
that should lead to caution. EF was significantly lower in the thrombus group and could
be therefore identified as a risk factor under the dual antiplatelet regime.
TCT-722
Single-Centre Experience of Left Atrial Appendage Closure. Role of
Carto/CT/MR in the Selection of Device Size
José Ramón López-Mínguez, Reyes González, Concepción Fernández, Manuel
Doblado, María E Fuentes, Javier Eldoayen, María Yuste, Juan M Nogales, Antonio
Merchán
Cardiology, Infanta Cristina University Hospital, Badajoz, Spain
Background: Closure of the left atrial appendage (LAA) is seen as an attractive
therapeutic option for nonvalvular atrial fibrillation patients with contraindications to
taking oral anticoagulants. Proper device size selection is crucial to ensuring proper
implantation and avoiding multiple attempts which, in turn, increase the risk of
complications. The object of this paper is to present our results and determine the
information that can be contributed by the use of the Carto system using MR or CT
images, with particular emphasis on the aspect of size selection.
Methods: The first 30 patients in our series which underwent implantation of the ACP
device were studied. After the first 5 cases, Carto RM was performed on 10 patients
and Carto CT on the following 15. The measurements obtained by transoesophageal
echocardiography (TEE) and angiography (A) were compared with those obtained by
CARTO/CT/MR (C). The influence of the three techniques on the correct selection of
the final device size was assessed.
Results: In only one case the device could not be implanted and in only three cases it
was necessary to change the final device size selected. There were not cardiac
complications. The superoinferior (SI) axis was usually found to be longer than the
anteroposterior one (in 22 out of 25) (20.3±3.5mm vs 18.02±2.9mm) and in most cases,
it determined device size. In only 33.3% of cases there was found to be agreement
between all three measurement techniques, A, TEE and C, leading to an accurate device
size selection. Measurements using C were definitive for the selection of the ACP
device in 87.5% of cases, versus 75%, for A and 45.8% for TEE. In 20.8% of cases
(5/24) C correctly influenced the change in device size selected using the other
techniques. Moreover, it offered information on the orientation of the LAA, thus
helping to establish the implantation strategy. Mean measurement of implanted ACP
device was 22.26±3.22 mm.
Conclusion: Performing CARTO/CT/MR assists in the implantation of the ACP device
and reduces the need for changing device and, indirectly, potential complications.
TCT-723
Percutaneous Pericardiocentesis Versus Surgical Pericardial Drainage In The
Treatment Of Symptomatic Pericardial Effusions: Recurrence And
Complication Rates
A. Garvey Rene1, Yehuda E Paz1, Adam J Saltzman1, Philip Green1, Ahmed
Hassanin2, George Dangas3, Leroy Rabbani1
1Columbia University College of Physicians and Surgeons, Division of Cardiology,
New York, NY; 2Cardiovascular Research Foundation, New York, NY; 3Mount Sinai
School of Medicine, Division of Cardiology, New York, NY
Background: Since the optimal treatment for symptomatic pericardial effusion has
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